MedPath

The Letrozole Administration During Luteal Phase

Phase 3
Not yet recruiting
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Registration Number
NCT02686151
Lead Sponsor
The Affiliated Hospital of Inner Mongolia Medical University
Brief Summary

To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment group.

Detailed Description

1. Object:

Infertility patients who frozen all embryos due to the risk of OHSS were randomized allocated to letrozole or polygeline injection group. Inclusion criteria meet one of the following conditions: (1) oocyte is more than or equal to 20; (2) human chorionic gonadotropin (hCG) injection on serum estradiol levels greater than or equal to 5000 pmol/L; (3) on the day of oocyte unilateral or bilateral ovarian diameter greater than or equal to 10 cm (4) follicle puncture is larger than or equal to number 20. After the informed consent was signed, letrozole or polygeline injection was randomized allocated after oocyte retrieval. OHSS was determined according to Golan diagnosis standards.

2. Clinical data:

Including age, infertility duration, body mass index (BMI), basic follicle-stimulating hormone (FSH) and luteinizing hormone (LH), antral follicle number (AFC), Gn dosage, estradiol level on hCG injection day, the number of oocytes, the number of embryos, early onset OHSS incidence, and the existence of ascites.

3. Reproductive hormone levels:

1, 4, 7, days after taken letrozole, and the supernatant was collected for serum reproductive hormone test.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Polygeline InjectionPolygeline500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection,once a day for 2 days
Polygeline InjectionSodium Chloride500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection,once a day for 2 days
Polygeline Injectiondexamethasone500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection,once a day for 2 days
letrozoleLetrozole2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
Primary Outcome Measures
NameTimeMethod
The incidence of early OHSSone year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Affiliated Hospital of Inner Mongolia Medical University

🇨🇳

Inner Mongolia, China

© Copyright 2025. All Rights Reserved by MedPath